Compare NMFC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMFC | ALLO |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.2M | 707.6M |
| IPO Year | N/A | 2018 |
| Metric | NMFC | ALLO |
|---|---|---|
| Price | $7.16 | $2.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $8.63 | $8.35 |
| AVG Volume (30 Days) | 480.0K | ★ 6.9M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 15.27% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $142,416.42 |
| P/E Ratio | $12.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.29 | $0.99 |
| 52 Week High | $10.90 | $4.46 |
| Indicator | NMFC | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 26.88 | 52.42 |
| Support Level | N/A | $1.85 |
| Resistance Level | $8.17 | $2.36 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 4.28 | 61.78 |
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).